{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:04:42Z","timestamp":1759017882890,"version":"3.44.0"},"reference-count":6,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.clinthera.2019.12.015","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T07:45:58Z","timestamp":1579247158000},"page":"374-375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Does Ranolazine Reduce Pain Perception With Cerebral Effect?"],"prefix":"10.1016","volume":"42","author":[{"given":"Hatice","family":"Tolunay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.12.015_bib1","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.clinthera.2019.08.008","article-title":"Effects of the antianginal drugs ranolazine, nicorandil, and \u0131vabradine on coronary microvascular function in patients with nonobstructive coronary artery disease: a meta-analysis of randomized controlled trials","volume":"41","author":"Zhu","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2019.12.015_bib2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jcmg.2011.03.007","article-title":"Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc Imaging","volume":"4","author":"Mehta","year":"2011","journal-title":"JACC Cardiovascular Imaging"},{"year":"2008","series-title":"European Medicines Agency Evaluation of Medicines for Human Use","key":"10.1016\/j.clinthera.2019.12.015_bib3"},{"key":"10.1016\/j.clinthera.2019.12.015_bib4","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.neuropharm.2012.01.021","article-title":"Block of Na+ currents and suppression of action potentials in embryonic rat dorsal root ganglion neurons by ranolazine","volume":"62","author":"Hirakawa","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.clinthera.2019.12.015_bib5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jns.2016.08.047","article-title":"Ranolazine: a potential treatment for refractory neuropathic pain","volume":"369","author":"Gould","year":"2016","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.clinthera.2019.12.015_bib6","first-page":"360","article-title":"ISMP adverse drug reactions","volume":"48","year":"2013","journal-title":"Hosp Pharm"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:52:24Z","timestamp":1758963144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819305995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0149291819305995"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.12.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does Ranolazine Reduce Pain Perception With Cerebral Effect?","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}